75
Participants
Start Date
January 13, 2024
Primary Completion Date
March 31, 2025
Study Completion Date
July 31, 2025
TQB2618 injection
TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
Penpulimab injection
Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
Anlotinib hydrochloride capsules
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
NOT_YET_RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Huai Nan First People's Hospital, Huainan
RECRUITING
Fuyang Cancer Hospital, Fuyang
NOT_YET_RECRUITING
Affiliated Hospital of Jining Medical University, Jining
RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Meizhou People's Hospital (Huangtang Hospital), Meizhou
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
NOT_YET_RECRUITING
The people's hospital of Leshan, Leshan
NOT_YET_RECRUITING
Mianyang central hospital, Mianyang
NOT_YET_RECRUITING
The First Affiliated Hospital of Air Force Medical University, Xi'an
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an
NOT_YET_RECRUITING
Shanxi Cancer Hospital, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY